NeuroPace Q2 revenue slightly beats estimates
NPCE•Raises 2026 outlook
NeuroPace raised its 2026 revenue guidance to $99.5 million-$101.5 million, from $99 million-$101 million.
It now expects 2026 non-GAAP gross margin of 82.0%-83.0%, up from 81.5%-82.5%, and an adjusted EBITDA loss of $7.5 million-$8.5 million, compared with a prior outlook for a $8.5 million-$9.5 million loss.
Wall Street's median 12-month price target for NeuroPace, Inc. is $20.00, about 34.4% above its August 10 closing price of $14.88.
Q2 revenue slightly beats estimates
NeuroPace said second-quarter revenue grew 17% year over year, slightly beating analyst expectations, as adoption of its RNS System for focal epilepsy increased.
The company said the quarter marked new all-time highs in active prescribers, accounts and patient pipeline.
Loss narrows as RNS adoption increases
NeuroPace reported a second-quarter net loss of $6.20 million, or $0.18 per share, compared with the prior year. Gross profit was and operating expenses were .
